Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care

AstraZeneca Pharma India discontinues manufacturing of Imdur

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851

Cadila launches Cadilose for constipation and hepatic encephalopathy

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region

OneSource Specialty Pharma strengthens its board by appointing new directors

These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance

Zydus to acquire majority stake in Amplitude Surgical, France

Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies

Glenmark Nutrition Awards 2025 celebrates innovation and impact in fight against malnutrition

403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.

Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics

Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise

Unichem Laboratories receives 4 observations from USFDA for Pithampur API facility

The company will provide the necessary response on these observations to USFDA within stipulated 15 days